Design Therapeutics reports Q3 2026 results, FA registrational update due in Q4
The company says a Friedreich ataxia regulatory plan update is coming this quarter, with 12-week trial data to follow in early 2027.
Design Therapeutics reported third quarter 2026 results on November 4, 2026, alongside updates across its GeneTAC pipeline. For Friedreich ataxia, the company said the Phase 1/2 multiple ascending dose RESTORE-FA trial of DT-216P2 is ongoing, with an update on registrational plans due in the fourth quarter of 2026 and data after 12 weeks of treatment expected in the first quarter of 2027.1 CEO Pratik Shah said the company is focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia.1
In myotonic dystrophy type-1, a Phase 1 multiple-ascending dose trial of DT-818 is ongoing, testing a GeneTAC small molecule meant to cut transcription of the mutant DMPK allele in DM1 patients.1 Design expects data from that trial in 2027.1
For Fuchs Endothelial Corneal Dystrophy, a Phase 2 biomarker study of DT-168 is underway, looking at safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data expected in 2027.1 In Huntington's disease, Design continues preclinical work on several candidate molecules.1
On financials, the company said cash, cash equivalents and investment securities totaled $208.6 million as of September 30, 2026.1 The release describes this position as providing what the company calls strong financial runway. Net loss for the quarter was $20.3 million for the quarter ended September 30, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.